Miniatura

Fitxers

ofab439.pdf (477.35 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-08-25

Llicència de publicació

cc-by-nc-nd (c) Smith, Graham et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/181451

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1093/ofid/ofab439

Resum

Background. In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years. Methods. After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/Q4W groups) or switched from oral ART to Q8W or Q4W LA therapy (extension-switch groups). Endpoints assessed included proportion of participants with HIV-1 RNA <50 copies/mL (Snapshot algorithm) and adverse events (AEs). Results. At week 256, 186 of 230 (81%) participants in randomized Q8W/Q4W groups and 41 of 44 (93%) participants in extension-switch groups had HIV-1 RNA <50 copies/mL. No protocol-defined virologic failures occurred after week 48. Injection wsite reactions infrequently resulted in discontinuation (4 [2%] and 1 [2%] participants in randomized Q8W/Q4W and extension-switch groups, respectively). Three participants in randomized Q8W/Q4W groups experienced drug-related serious AEs, including 1 fatal serious AE (Q4W group); none occurred in extension-switch groups. Of 25 participants with AEs leading to withdrawal, 20 were in the randomized Q4W group; no AE leading to withdrawal occurred in >1 participant. Conclusions. Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection.

Matèries

Inhibidors de la integrasa, Nucleòsids, Immunodeficiència

Matèries (anglès)

Integrase inhibitors, Nucleosides, Immunodeficiency

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SMITH, Graham, HENRY, W. keith, PODZAMCZER PALTER, Daniel, MASIÁ, Maria del mar, BETTACCHI, Christopher j., ARASTEH, Keikawus, JAEGER, Hans, KHUONG-JOSSES, Marie-aude, MONTES, Maria luisa, STELLBRINK, Hans-jürgen, YAZDANPANAH, Yazdan, RICHMOND, Gary j., SUTTON, Kenneth c., ZHANG, Feifan, MCCOIG, Cynthia c., ST. CLAIR, Marty h., VANDERMEULEN, Kati, VAN SOLINGEN-RISTEA, Rodica, SMITH, Kimberly y., MARGOLIS, David a., SPREEN, William r.. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study. _Open Forum Infectious Diseases_. 2021. Vol. 8, núm. 9. [consulta: 8 de febrer de 2026]. [Disponible a: https://hdl.handle.net/2445/181451]

Exportar metadades

JSON - METS

Compartir registre